Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 1/20 | 0.42 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.42 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | F2 | P00734 | 1/20 | 0.32 |
| ▸ | F10 | P00742 | 1/20 | 0.32 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.32 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3373249 | 1.00 | ADRB3 (0.42) | ADRB3ADRA2BADRA2CCYP3A4GAA | |
| SCHEMBL7940307 | 1.00 | ADRB3 (0.42) | ADRB3ADRA2BADRA2CCYP3A4GAA | |
| SCHEMBL3373243 | 1.00 | ADRB3 (0.42) | ADRB3ADRA2BADRA2CCYP3A4GAA | |
| SCHEMBL15487382 | 1.00 | ADRB3 (0.42) | ADRB3ADRA2BADRA2CCYP3A4GAA | |
| SCHEMBL5530641 | 0.93 | ADRB3 (0.45) | ADRB3ADRA2BADRA2CCYP3A4GAA | |
| SCHEMBL5534015 | 0.93 | ADRB3 (0.45) | ADRB3ADRA2BADRA2CCYP3A4GAA | |
| SCHEMBL2624064 | 0.93 | ADRB3 (0.45) | ADRB3ADRA2BADRA2CCYP3A4GAA | |
| SCHEMBL7876742 | 0.93 | ADRB3 (0.45) | ADRB3ADRA2BADRA2CCYP3A4GAA | |
| SCHEMBL5534012 | 0.93 | ADRB3 (0.45) | ADRB3ADRA2BADRA2CCYP3A4GAA | |
| SCHEMBL3058266 | 0.93 | ADRB3 (0.45) | ADRB3ADRA2BADRA2CCYP3A4GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150080569-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2015-03-19 | — | — | US | disclosed |
| US-8809266-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-20140051626-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2014-02-20 | — | — | US | disclosed |
| US-20130274439-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2013-10-17 | — | — | US | disclosed |
| US-8513186-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2013-08-20 | — | — | US | disclosed |
| US-8513186-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2013-08-20 | — | — | US | disclosed |
| US-20130053577-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2013-02-28 | — | — | US | disclosed |
| US-8283442-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2012-10-09 | — | — | US | disclosed |
| US-20120190866-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2012-07-26 | — | — | US | disclosed |
| US-8178491-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-20090186869-A1 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2009-07-23 | — | — | US | disclosed |
| US-20090186869-A1 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2009-07-23 | — | — | US | disclosed |
| US-7504378-B2 | Macrocyclic peptides active against the hepatitis C virus | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-03-17 | — | — | US | disclosed |
| US-7504378-B2 | Macrocyclic peptides active against the hepatitis C virus | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-03-17 | — | — | US | disclosed |
| US-20090035272-A1 | Pyridazinonyl Macrocyclic Hepatitis C Serine Protease Inhibitors | ENANTA PHARMACEUTICALS, INC. | 2009-02-05 | — | — | US | disclosed |
| US-20090035272-A1 | Pyridazinonyl Macrocyclic Hepatitis C Serine Protease Inhibitors | ENANTA PHARMACEUTICALS, INC. | 2009-02-05 | — | — | US | disclosed |
| WO-2009005676-A2 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2009-01-08 | — | — | WO | disclosed |
| US-20070249637-A1 | Inhibitors Of Hepatitis C Virus Protease, And Compositions And Treatments Using The Same | COLLINS MICHAEL R | 2007-10-25 | — | — | US | disclosed |
| US-20070249637-A1 | Inhibitors Of Hepatitis C Virus Protease, And Compositions And Treatments Using The Same | COLLINS MICHAEL R | 2007-10-25 | — | — | US | disclosed |
| WO-2006043145-A1 | INHIBITORS OF HEPATITIS C VIRUS PROTEASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME | PFIZER INC. (US) | 2006-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090035272-A1 | Pyridazinonyl Macrocyclic Hepatitis C Serine Protease Inhibitors | PRSS1, SPINT2, TMPRSS4 | ADRB3 4135/4885ADRA2B 4438/4885ADRA2C 3858/4885 |
| US-20130274439-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | ADRB3 4323/4885ADRA2B 4738/4885ADRA2C 4546/4885 |
| US-20130053577-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | ADRB3 4323/4885ADRA2B 4738/4885ADRA2C 4546/4885 |
| US-20090186869-A1 | Antiviral compounds | MAVS, EIF2AK2, ZC3HAV1 | ADRB3 4323/4885ADRA2B 4738/4885ADRA2C 4546/4885 |
| US-20120190866-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | ADRB3 4323/4885ADRA2B 4738/4885ADRA2C 4546/4885 |
| US-20070249637-A1 | Inhibitors Of Hepatitis C Virus Protease, And Compositions And Treatments Using The Same | SERPINB1, CTSC, CTSV | ADRB3 3055/4885ADRA2B 4291/4885ADRA2C 3460/4885 |
| US-20140051626-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | ADRB3 4323/4885ADRA2B 4738/4885ADRA2C 4546/4885 |
| US-20150080569-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | ADRB3 4323/4885ADRA2B 4738/4885ADRA2C 4546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.